| 2026-10-22 17:11 |
8-K |
["1.01", "2.02", "8.01"] |
other |
0.05
|
Public equity offering by Disc Medicine; no M&A signals present. |
SEC · detail |
| 2026-10-19 07:08 |
8-K |
["7.01", "8.01"] |
other |
0.05
|
Clinical trial success announcement for bitopertin; no M&A, activist, or strategic transaction signals present. |
SEC · detail |
| 2026-09-10 08:48 |
8-K |
["7.01", "8.01", "9.01"] |
other |
0.05
|
Clinical trial results announcement for DISC-3405 in polycythemia vera; no M&A signals present. |
SEC · detail |
| 2026-07-30 08:32 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q2 2026 earnings announcement with financial results and corporate update; no M&A signals. |
SEC · detail |
| 2026-06-30 16:16 |
8-K |
["1.01", "2.03"] |
other |
0.05
|
Loan agreement amendment extending drawdown periods and modifying covenants; no M&A signal. |
SEC · detail |
| 2026-06-24 16:22 |
8-K |
["5.07"] |
other |
0.00
|
Routine annual meeting voting results; no M&A signals present. |
SEC · detail |
| 2026-05-05 08:32 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings announcement with corporate update. No M&A signals detected. |
SEC · detail |